

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

**FIRST QUARTERLY REPORT FOR THE
THREE MONTHS ENDED MARCH 31, 2024**

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The report of the unaudited results (the “**First Quarterly Report**”) of the Group for the three months ended March 31, 2024 (the “**Reporting Period**”) is provided. The financial information contained in the First Quarterly Report was prepared in accordance with the Chinese Accounting Standards for Business Enterprises and has not been audited by the auditor of the Group. Potential investors and shareholders of the Company are advised to exercise caution when dealing in the shares of the Company.

The First Quarterly Report is written in both Chinese and English. In the case of any discrepancies, the Chinese version of the First Quarterly Report shall prevail.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, April 29, 2024

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive directors, Ms. Nisa Bernice Wing-Yu LEUNG as a non-executive director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive directors.

IMPORTANT NOTICE

The board (the “**Board**”) of directors (the “**Directors**”), the board of supervisors, the Directors, supervisors and senior management of the Company confirm that the contents of the First Quarterly Report are true, accurate and complete, and that there are no false representations, misleading statements contained or material omissions, and are jointly and severally responsible for the liabilities arising from the First Quarterly Report of the Company.

The legal representative of the Company, the person in charge of accounting affairs and the person in charge of the accounting department confirm that the financial statements contained in the First Quarterly Report are true, accurate and complete.

Whether the First Quarterly Report has been audited.

Yes No

I. BASIC INFORMATION OF THE GROUP

1.1 Key financial data and indicators

Unit: Yuan; Currency: RMB

Item	Amount for the Reporting Period	Increase/(decrease) as compared with the corresponding period of 2023 (%)
Operating revenue	114,282,281.78	13.65
Net profit attributable to shareholders of the listed company	(170,095,866.61)	Not applicable
Net profit after deduction of non-recurring profit or loss attributable to shareholders of the listed company	(178,676,681.71)	Not applicable
Net cash flows from operating activities	(108,195,674.35)	Not applicable
Basic earnings per share (RMB/Share)	(0.69)	Not applicable
Diluted earnings per share (RMB/Share)	(0.69)	Not applicable
Weighted average return on net assets (%)		Decreased by 1.19 percentage points
	(3.28)	
Total research and development investment	124,328,450.39	(17.59)
Proportion of research and development investment to operating revenue (%)		Decreased by 41.25 percentage points
	108.79	

Item	As at the end of the Reporting Period	As at the end of 2023	Increase/(decrease) as at the end of the Reporting Period as compared with the end of 2023 (%)
Total assets	8,568,692,147.63	9,318,769,372.66	(8.05)
Total owners' equity attributable to the shareholders of the listed company	5,106,502,460.80	5,274,604,094.18	(3.19)

1.2 Items and amounts of non-recurring profits or losses

√ Applicable □ Not applicable

Unit: Yuan; Currency: RMB

Item	Amount for the Reporting Period	Notes
Government grants recognized though profit or loss for the current period excluding those closely related to the Company's ordinary operations and granted on an ongoing basis under the national policies according to certain fixed quota of amount or volume	3,338,399.00	
Except for effective hedging businesses that relate to the Company's normal business operations, profit or loss from fair value changes on financial assets held-for-trading, derivative financial assets, financial liabilities held-for-trading and derivative financial liabilities, and investment income from disposal of financial assets held-for-trading, derivative financial assets, financial liabilities held-for-trading, derivative financial liabilities and other debt investment	6,164,241.71	
Expense recognized one-time due to the cancellation or modification of share-based payments	(67,080.00)	
Other non-operating revenue and expenses other than the foregoing items	(1,719.70)	
Less: Effect of income tax	853,025.91	
Total	8,580,815.10	

Explanation on the Company’s recognition of the items not listed in “Explanatory Announcement No. 1 on Information Disclosure of Companies Offering Securities to the Public – Non-recurring Profit or Loss” as non-recurring gains and losses items with significant amount and definition of the non-recurring gains and losses items listed in the “Explanatory Announcement No. 1 on Information Disclosure of Companies Offering Securities to the Public – Non-recurring Profit or Loss” as recurring gains or losses items

Applicable Not applicable

1.3 Details of and reasons for material changes in the key financial data and indicators

Applicable Not applicable

Item	Increase/ (decrease) (%)	Reasons
Proportion of research and development investment to operating revenue (%)	Decreased by 41.25 percentage points	Proportion of research and development investment to operating revenue decreased by 41.25 percentage points compared with the corresponding period last year, primarily due to the fact that the operating revenue of the Company increased as compared with corresponding period last year; the Company strengthened management and control over research and development expenses, reduced investment related to COVID-19 vaccines.
Net cash flows from operating activities	Not applicable	Net cash outflows from operating activities decreased by RMB237.2 million compared with the corresponding period last year (68.68% narrower), primarily due to the increase in collection of trade receivables and the decrease in payment of raw materials, testing and clinical services and labor costs.

Note: In the first quarter of 2024, the Company incurred a decrease in total assets and total liabilities and a loss of RMB70,511,874.94 from the deconsolidation of CanSino SPH Biologics Inc. (“CanSino SPH”). After excluding the impact of this one-off special loss, the net loss attributable to shareholders of the listed company was RMB99,583,991.67, with a decreased loss of RMB39,963,631.00 compared with the corresponding period last year; the net loss after deduction of non-recurring profit or loss attributable to shareholders of the listed company was RMB108,164,806.77, with a decreased loss of RMB70,476,785.94 compared with the corresponding period last year.

II. SHAREHOLDERS INFORMATION OF THE GROUP

2.1 Total number of ordinary shareholders, number of preferred shareholders with voting rights restored and shareholding of the top ten shareholders

Unit: Share

Total number of ordinary shareholders as at the end of the Reporting Period	21,770	Total number of preferred shareholders with voting rights restored as at the end of the Reporting Period (if any)	Not applicable
---	--------	---	----------------

Shareholdings of the top ten shareholders (not including shares lent under refinancing business)

Name of Shareholder	Nature of shareholder	Number of shares	Percentage (%)	Number of shares subject to selling restriction held	Number of restricted shares including shares lent by refinancing	Pledged or frozen Status of shares	Number of Shares
HKSCC NOMINEES LIMITED	Overseas corporation	98,066,897	39.63	–	–	Unknown	–
Xuefeng YU	Overseas natural person	17,874,200	7.22	–	–	None	0
Tao ZHU	Domestic natural person	17,874,200	7.22	–	–	None	0
Dongxu QIU	Overseas natural person	17,114,200	6.92	–	–	None	0
Helen Huihua MAO	Overseas natural person	15,195,441	6.14	–	–	None	0
Shanghai Qianxiyi Enterprise Management Partnership (Limited Partnership)	Domestic non-state-owned legal person	3,474,600	1.40	–	–	None	0
Shanghai Qianxirui Enterprise Management Partnership (Limited Partnership)	Domestic non-state-owned legal person	3,299,475	1.33	–	–	None	0
Future Industry Investment Fund (Limited Partnership)	Domestic non-state-owned legal person	2,883,810	1.17	–	–	None	0
Ge SUN	Domestic natural person	1,403,742	0.57	–	–	None	0
Shanghai Qianxizhi Enterprise Management Partnership (Limited Partnership)	Domestic non-state-owned legal person	1,207,150	0.49	–	–	None	0

Shareholdings of the top ten shareholders not subject to the selling restrictions

Name of Shareholder	Number of shares not subject to selling restrictions at the end of the Reporting Period	Class and number of Shares	
		Class	Number
HKSCC NOMINEES LIMITED	98,066,897	Overseas listed foreign shares	98,066,897
Xuefeng YU	17,874,200	RMB ordinary shares	17,874,200
Tao ZHU	17,874,200	RMB ordinary shares	17,874,200
Dongxu QIU	17,114,200	RMB ordinary shares	17,114,200
Helen Huihua MAO	15,195,441	RMB ordinary shares	15,195,441
Shanghai Qianxiyi Enterprise Management Partnership (Limited Partnership)	3,474,600	RMB ordinary shares	3,474,600
Shanghai Qianxirui Enterprise Management Partnership (Limited Partnership)	3,299,475	RMB ordinary shares	3,299,475
Future Industry Investment Fund (Limited Partnership)	2,883,810	RMB ordinary shares	2,883,810
Ge SUN	1,403,742	RMB ordinary shares	1,403,742
Shanghai Qianxizhi Enterprise Management Partnership (Limited Partnership)	1,207,150	RMB ordinary shares	1,207,150

Description on the related party relationship or parties acting in concert among the aforesaid shareholders Xuefeng YU, Tao ZHU, Dongxu QIU, Helen Huihua MAO, Shanghai Qianxiyi Enterprise Management Partnership (Limited Partnership), Shanghai Qianxirui Enterprise Management Partnership (Limited Partnership) and Shanghai Qianxizhi Enterprise Management Partnership (Limited Partnership) are acting in concert. Apart from the above, the Company is not aware of any related party relationship between the shareholders or whether they are parties acting in concert.

Description on participation in margin trading and refinancing business by the top ten shareholders and the top ten shareholders not subject to the selling restrictions (if any) Not applicable

Note: The shares held by HKSCC NOMINEES LIMITED (Hong Kong Securities Clearing Company Limited) are the total number of shares in the accounts of the holders of H shares of the Company traded on the Hong Kong Securities Clearing Company Limited trading platform, excluding the number of H shares held by the controlling shareholders of the Company.

Information of participation in margin trading and refinancing business by shareholders holding more than 5% or more of the shares, the top ten shareholders and the top ten shareholders not subject to the selling restrictions

Applicable Not applicable

Change of top ten shareholders and the top ten shareholders not subject to the selling restrictions due to lending/return of refinancing business over the last period

Applicable Not applicable

III. OTHER IMPORTANT MATTERS

Other important information in relation to the operation of the Company during the Reporting Period to which investors are advised to pay attention

Applicable Not applicable

1. Deconsolidation of CanSino SPH

The initial cooperation period as stipulated in the concert party agreement entered into by and between the Company and Shanghai Biomedical Industry Equity Investment Fund Partnership (Limited Partnership) expired on February 2, 2024. Such agreement was automatically terminated. Upon the termination of the concert party agreement, the Company no longer controls more than half of the equity interest in CanSino SPH or more than half of the seats of the board of directors of CanSino SPH, resulting in a loss of control over CanSino SPH. As a result, CanSino SPH will become a joint venture of the Company and will no longer be included in the scope of the Company's consolidated statements. The Company's long-term equity investment in CanSino SPH will be converted from the cost method to the equity method of accounting.

2. Involvement in a Lawsuit in Brazil

The Company received the notice of a lawsuit in March 2024 from 3^a Vara Cível de Maringa/PR ("**Brazilian Court**") filed by Belcher Farmaceutica Ltda. ("**Belcher**"), claiming Brazilian Real 167 million (equivalent to approximately RMB241 million) in compensation for related losses, fees, and spiritual damage from the Company following the termination of the authorization to it to negotiate with the Brazilian government about the registration and commercialization of our COVID-19 vaccines in Brazil in 2021.

The Company has engaged a professional legal counsel to handle such lawsuit. Based on the current legal advice, we have strong defense position and it is unlikely that Belcher's claim will be supported by the Brazilian Court. Therefore, the management of the Company is in the view that it is not probable an outflow of economic benefits will be required to settle the claim. As of the date of this report, the Brazilian Court has yet to start hearing of this lawsuit.

IV. QUARTERLY REPORT

4.1 Audit opinion type of Quarterly Report

Applicable Not applicable

4.2 Financial Statements

CONSOLIDATED BALANCE SHEET

March 31, 2024

Prepared by: CanSino Biologics Inc.

Unit: Yuan; Currency: RMB; Type of audit: Unaudited

Item	As of March 31, 2024	As of December 31, 2023
Current assets:		
Monetary funds	2,583,090,201.23	2,821,595,241.10
Deposit reservation for balance		
Lending funds		
Financial assets held for trading	1,431,702,017.93	1,308,274,692.11
Derivative financial assets	811,347.57	1,295,056.72
Note receivables		
Trade receivables	595,129,615.03	636,882,259.80
Financing receivables		
Advances to suppliers	45,121,226.90	48,545,689.70
Premium receivables		
Reinsurance accounts receivable		
Receivable from subcontracting reserves		
Other receivables	10,320,560.03	5,715,751.49
Including: Interests receivable		
Dividend receivables		
Redemptory monetary capital for sale		
Inventories	355,418,384.95	352,847,638.45
Including: Data resources		
Contract assets		
Assets classified as held for sale		
Non-current assets due within one year		
Other current assets	2,248,966.25	5,671,447.24
Total current assets	5,023,842,319.89	5,180,827,776.61

Item	As of March 31, 2024	As of December 31, 2023
Non-current assets:		
Issuing of loans and advances		
Debt investments		
Other debt investments		
Long-term receivables		
Long-term equity investments	20,432,964.68	18,168,286.75
Investments in other equity instruments	–	–
Other non-current financial assets	150,228,448.12	122,145,322.16
Investment properties		
Fixed assets	1,425,690,263.41	1,697,842,713.48
Construction in progress	943,031,311.52	1,113,597,741.67
Bearer biological assets		
Oil-and-gas assets		
Right-of-use assets	21,156,687.03	202,006,210.71
Intangible assets	126,343,887.79	144,148,577.93
Including: Data resources		
Development disbursement	89,081,308.24	61,498,469.18
Including: Data resources		
Goodwill		
Long-term prepaid expenses	25,470,297.29	26,900,953.15
Deferred income tax assets	207,861,250.00	207,861,250.00
Other non-current assets	535,553,409.66	543,772,071.02
Total non-current assets	3,544,849,827.74	4,137,941,596.05
TOTAL ASSETS	8,568,692,147.63	9,318,769,372.66

Item	As of March 31, 2024	As of December 31, 2023
Current liabilities:		
Short-term borrowings	955,024,919.80	854,082,887.35
Borrowings from the Central Bank		
Borrowing funds		
Financial liabilities held for trading		
Derivative financial liabilities	23,726.47	973,158.88
Notes payables		
Trade payables	72,448,144.45	103,970,154.17
Advances from customers		
Contract liabilities	10,828,912.21	3,567,142.96
Financial assets sold for repurchase		
Absorbing deposit and interbank deposit		
Receivings from vicariously traded securities		
Receivings from vicariously sold securities		
Employee benefits payable	132,390,812.54	166,706,873.31
Taxes payable	37,373,083.26	48,195,985.15
Other payables	484,840,138.73	673,580,483.99
Including: Interests payable	–	310,647.01
Dividend payables		
Fees and commissions payable		
Reinsurance account payables		
Liabilities classified as held for sale		
Non-current liabilities due within one year	322,106,972.36	575,220,990.15
Other current liabilities	87,727,116.09	139,004,075.64
Total current liabilities	2,102,763,825.91	2,565,301,751.60
Non-current liabilities:		
Provision for insurance contracts		
Long-term borrowings	1,148,909,685.31	1,065,659,776.95
Bond payables		
Including: Preferred shares		
Perpetual bonds		
Lease liabilities	13,778,718.29	175,183,004.85
Long-term payables		
Long-term employee benefits payable		
Accrued liabilities		
Deferred income	188,245,532.07	216,717,600.10
Deferred income tax liabilities		
Other non-current liabilities	8,491,925.25	8,491,925.25
Total non-current liabilities	1,359,425,860.92	1,466,052,307.15
TOTAL LIABILITIES	3,462,189,686.83	4,031,354,058.75

Item	As of March 31, 2024	As of December 31, 2023
Owners' equity (or shareholders' equity):		
Paid-up capital (or share capital)	247,449,899.00	247,449,899.00
Other equity instruments		
Including: Preferred shares		
Perpetual bonds		
Capital reserves	6,575,200,351.21	6,573,528,919.71
Less: Treasury shares	106,173,421.67	106,173,421.67
Other comprehensive income	146,653.19	(176,148.54)
Special reserves		
Surplus reserves	118,388,703.29	118,388,703.29
General risk provisions		
Undistributed profits	(1,728,509,724.22)	(1,558,413,857.61)
Total owners' equity (or shareholders' equity)		
attributable to the parent company	5,106,502,460.80	5,274,604,094.18
Non-controlling interests	–	12,811,219.73
TOTAL OWNERS' EQUITY (OR SHAREHOLDERS' EQUITY)	5,106,502,460.80	5,287,415,313.91
TOTAL LIABILITIES AND OWNERS' EQUITY (OR SHAREHOLDERS' EQUITY)	8,568,692,147.63	9,318,769,372.66

Legal representative:
Xuefeng YU

*Person in charge of
accounting affairs:*
Ming LIU

*Person in charge of the
accounting department:*
Qun FU

CONSOLIDATED INCOME STATEMENT

From January to March, 2024

Prepared by: CanSino Biologics Inc.

Unit: Yuan; Currency: RMB; Type of audit: Unaudited

Item	First quarter of 2024 (From January to March)	First quarter of 2023 (From January to March)
I. Total revenue	114,282,281.78	100,553,241.30
Including: Operating Revenue	114,282,281.78	100,553,241.30
Interest income		
Earned premium		
Service charges and commission income		
II. Total costs	205,224,944.71	338,229,437.92
Including: Cost of operation	46,232,685.48	65,186,672.13
Interest payments		
Service charges and commission fee		
Surrender charge fee		
Net payments for insurance claims		
Extraction of insurance obligations net reserves		
Policyholder dividend expenses		
Reinsurance expenses		
Business taxes and surcharges	1,969,375.55	1,939,071.28
Selling expenses	46,585,864.69	54,983,176.06
Administrative expenses	37,068,694.05	60,546,916.48
Research and development expenses	96,745,611.33	149,765,069.58
Financial expenses	(23,377,286.39)	5,808,532.39
Including: Interest expenses	14,672,492.14	8,761,990.95
Interest income	23,433,364.72	22,518,819.34

Item	First quarter of 2024 (From January to March)	First quarter of 2023 (From January to March)
Add: Other income	8,591,840.84	33,378,539.03
Investment income (losses)	(75,386,450.79)	17,654,921.05
Including: Share of investment profit of associates and joint ventures	(13,129,311.96)	2,216.77
Derecognition gains on financial assets measured at amortised cost		
Exchange earnings (losses)		
Net gains from hedging exposure (losses)		
Gains arising from changes in fair value (losses)	(2,090,494.40)	7,168,705.67
Credit impairment loss (losses)	(7,246,408.65)	(11,181,001.27)
Asset impairment loss (losses)	(7,807,088.65)	(1,692,324.29)
Gains on assets disposal (losses)		
III. Operating profit (losses)	(174,881,264.58)	(192,347,356.43)
Add: Non-operating income	2,425.99	58,173.99
Less: Non-operating expenses	4,145.69	8,176,434.07
IV. Total profit (losses)	(174,882,984.28)	(200,465,616.51)
Less: Income tax expenses	–	(30,266,569.42)
V. Net profit (losses)	(174,882,984.28)	(170,199,047.09)
(I). Classified by operations continuity		
1. Net profit from continuing operations (losses)	(174,882,984.28)	(170,199,047.09)
2. Net profit from discontinued operations (losses)		
(II). Classified by ownership		
1. Net profit attributable to shareholders of the company (losses)	(170,095,866.61)	(139,547,622.67)
2. Net profit attributable to minority shareholders (losses)	(4,787,117.67)	(30,651,424.42)

Item	First quarter of 2024 (From January to March)	First quarter of 2023 (From January to March)
VI. Other comprehensive income, net of tax	322,801.73	33,286.82
(I). Other comprehensive income attributable to owners of the parent company, net of tax	322,801.73	33,286.82
1. Other comprehensive income that will not be reclassified to profit or loss		
(1) Changes in the re-measurement of defined benefit plans		
(2) Other comprehensive income accounted for using equity method, which will not be reclassified to profit or loss		
(3) Changes in fair value of investments in other equity instruments		
(4) Changes in fair value arising from the enterprise's credit risk		
2. Other comprehensive income that will be reclassified to profit or loss	322,801.73	33,286.82
(1) Other comprehensive income accounted for using equity method, which will be reclassified to profit or loss		
(2) Changes in fair value of other debt investments		
(3) Other comprehensive income arising from reclassifying financial assets		
(4) Provision for credit impairment of other debt investments		
(5) Cash flow hedging reserve		
(6) Exchange differences on translation of financial statements denominated in foreign currencies	322,801.73	33,286.82
(7) Others		
(II). Other comprehensive income attributable to minority shareholders, net of tax		

Item	First quarter of 2024 (From January to March)	First quarter of 2023 (From January to March)
VII. Total comprehensive profit	(174,560,182.55)	(170,165,760.27)
(I). Total comprehensive profit attributable to shareholders of the company	(169,773,064.88)	(139,514,335.85)
(II). Total comprehensive profit attributable to minority shareholders	(4,787,117.67)	(30,651,424.42)
VIII. Earnings per share		
(I). Basic earnings per share (RMB/share)	(0.69)	(0.57)
(II). Diluted earnings per share (RMB/share)	(0.69)	(0.57)

Under the circumstances that business combination under common control was effected in the current period, the net profit recognized by the merged party before the combination was RMB0, and the net profit recognized by the merged party in the corresponding period of last year was RMB0.

<i>Legal representative:</i> Xuefeng YU	<i>Person in charge of accounting affairs:</i> Ming LIU	<i>Person in charge of the accounting department:</i> Qun FU
---	---	--

CONSOLIDATED STATEMENTS OF CASH FLOWS

From January to March, 2024

Prepared by: CanSino Biologics Inc.

Unit: Yuan; Currency: RMB; Type of audit: Unaudited

Item	First quarter of 2024 (From January to March)	First quarter of 2023 (From January to March)
I. Cash flows from operating activities:		
Cash received from sales of goods and rendering of services	133,749,739.50	55,919,886.87
Net increase in customer deposits and interbank deposit payment		
Net increase in borrowing from the Central Bank		
Net increase in funds borrowed from other financial institutions		
Cash received from the receipt of the original insurance contract premiums		
Net cash received from reinsurance business		
Net increase in deposit of the insured and investment fund		
Interest, fees and commission in cash		
Net increase in funds borrowed		
Net increase in capital for repurchase business		
Net cash received from customer for acting as securities trading agent		
Refund of taxes received	27,814,191.17	17,027,704.90
Cash received relating to other operating activities	14,084,401.72	67,350,459.27
Subtotal of cash inflow from operating activities	175,648,332.39	140,298,051.04
Cash paid for goods and services	18,228,143.28	101,507,760.17
Net increase in customer loans and advances		
Net increase in placements with the Central Bank and Interbank		
Cash paid for claims on original insurance contract		
Net increase in lending funds		
Cash paid for interest, fees, and commissions		
Cash paid for policy dividend		
Cash paid to and on behalf of employees	124,057,842.57	156,793,016.86
Payments of taxes	1,097,063.13	23,938,150.16
Cash paid relating to other operating activities	140,460,957.76	203,464,223.79
Subtotal of cash outflows from operating activities	283,844,006.74	485,703,150.98
Net cash flows from operating activities	(108,195,674.35)	(345,405,099.94)

Item	First quarter of 2024 (From January to March)	First quarter of 2023 (From January to March)
II. Cash flows from investing activities:		
Cash received from disposal of investments	1,995,375,430.56	2,700,000,000.00
Cash received from return on investments	42,567,011.55	17,652,704.28
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	–	–
Net cash received from disposal of subsidiaries and other business units	–	–
Cash received relating to other investing activities	598,314,000.00	69,583,000.00
Subtotal of cash inflows from investing activities	2,636,256,442.11	2,787,235,704.28
Cash paid to acquire fixed assets, intangible assets and other long-term assets	134,415,331.63	215,235,503.03
Cash paid to acquire investments	2,149,442,100.00	2,140,000,000.00
Net increase in pledged loans		
Net cash paid to acquire subsidiaries and other business units		
Cash paid relating to other investing activities	77,387,782.04	604,008,600.00
Subtotal of cash outflows from investing activities	2,361,245,213.67	2,959,244,103.03
Net cash flows from investing activities	275,011,228.44	(172,008,398.75)
III. Cash flows from financing activities:		
Cash received from capital contributions		
Including: Cash received from capital contributions of minority shareholders of subsidiaries		
Cash received from borrowings	315,479,294.09	409,782,848.79
Cash received relating to other financing activities	–	142,400.64
Subtotal of cash inflows from financing activities	315,479,294.09	409,925,249.43
Cash paid for repayments of debts	149,407,000.00	392,161,855.86
Cash paid for distribution of dividends, profits or interest payment	16,788,906.04	23,056,733.70
Including: Dividends and profits paid to minority shareholders by subsidiaries		
Cash paid relating to other financing activities	1,908,709.30	5,181,466.36
Subtotal of cash outflows from financing activities	168,104,615.34	420,400,055.92
Net cash flow from financing activities	147,374,678.75	(10,474,806.49)

Item	First quarter of 2024 (From January to March)	First quarter of 2023 (From January to March)
IV. Effect of foreign exchange rate changes on cash and cash equivalents	14,618,020.10	(19,485,753.97)
V. Net increase in cash and cash equivalents	328,808,252.94	(547,374,059.15)
Add: Balance of cash and cash equivalents at the beginning of the period	2,046,099,121.63	3,391,267,855.28
VI. Balance of cash and cash equivalents at the end of the Period	2,374,907,374.57	2,843,893,796.13

Legal representative:
Xuefeng YU

*Person in charge of
accounting affairs:*
Ming LIU

*Person in charge of the
accounting department:*
Qun FU

Adjustment to the financial statements at the beginning of the first year of adopting new accounting standards and standard interpretations since 2024

Applicable Not applicable

1. *The Interim Provisions on the Accounting Treatment of Enterprise Data Resources (CK [2023] No. 11)*

On August 1, 2023, the Ministry of Finance issued the “Interim Provisions on the Accounting Treatment of Enterprise Data Resources”, clarifying the accounting treatment provisions related to enterprise data resources. The Group has implemented the provisions since January 1, 2024. It was assessed that such matter does not involve the adjustments to the financial statements at the beginning of the first year of implementation.

2. *The Interpretation of Accounting Standards for Business Enterprises No. 17 (CK [2023] No. 21)*

On October 25, 2023, the Ministry of Finance issued the “Interpretation of Accounting Standards for Business Enterprises No. 17”, which regulates the classification of current liabilities and non-current liabilities, disclosure of supplier financing arrangements, and accounting treatment of sale-and-leaseback transactions. Specific requirements were made respectively from presentation, disclosure and transition from old to new. The Group has implemented the above provisions since January 1, 2024. It was assessed that such matter does not involve the adjustments to the financial statements at the beginning of the first year of implementation.

The announcement is hereby made.

Board of CanSino Biologics Inc.